Navigation Links
Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia
Date:4/23/2014

Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine and daunorubicin, are showing better responses than patients treated with the standard drug formulation.

"Acute myeloid leukemia is an aggressive blood cancer with very low rates of treatment success, especially in older patients," explained Jeffrey Lancet, M.D., senior member of the Department of Malignant Hematology and chief of the Leukemia Section at Moffitt.

AML is diagnosed in approximately 19,000 people in the United States each year and results in over 10,000 deaths annually. Many patients with AML are older and have additional medical conditions, which makes treatment difficult. Only 50 percent of patients respond to existing therapies and the average survival time is less than 1 year. Therefore, researchers are trying to find new treatment options to increase survival.

The phase 2 study included 126 newly diagnosed AML patients from 18 cancer centers across the United States and Canada. The patients received the standard chemotherapeutic agents, cytarabine and daunorubicin, or the novel drug combination CPX-351.

"Patients with AML who received CPX-351 had a higher likelihood of remission than patients who received standard chemotherapy," said Lancet, who is the principal investigator and lead author of this study. "In addition, CPX-351 led to longer survival in the large subset of patients whose AML arose out of a previously diagnosed hematologic disorder, such as myelodysplastic syndrome."

Scientists know that cytarabine and daunorubicin work best in a particular concentration ratio. Unfortunately, it is difficult to maintain that ratio in the body when the drugs are administered; therefore, they don't work as effectively as they could. The drug CPX-351 is composed of subst
'/>"/>

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Moffitt researchers find cancer therapies affect cognitive functioning among breast cancer survivors
2. Moffitt Cancer Center researchers: Quality of life as important as quantity of life
3. Moffitt Cancer Center researchers working at frontiers of melanoma research
4. Moffitt researchers find adolescents with cancer concerned about their future reproductive health
5. Moffitt researcher publishes book on nutritional management of cancer treatment effects
6. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
7. Researchers creating designer lymph nodes based on Moffitts Total Cancer Care initiative
8. Moffitt Cancer Center researchers identify drivers of sarcoma growth and survival
9. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
10. Moffitt researcher, colleagues find success with new immune approach to fighting some cancers
11. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 According to the Nasal Polyps Treatment ... comprehensive guide that teaches people how to cure their ... uncovers to readers the horrible truth about conventional treatments for ... inside this book, people will learn how to prevent ... and nasal infections. , Nasal Polyps Treatment Miracle, as it ...
(Date:7/30/2014)... CA (PRWEB) July 30, 2014 ... and physician communication, launched an Observation Result (ORU) ... the hospital. pMD’s cardiology customers are using the ... revenue for their test interpretations for electrocardiograms, echocardiograms, ... tests in the hospital, the cardiology system produces ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Paul Mata, CEO ... Make More Money in 30 Days” E-book. The e-book includes ... use to make extra cash. Examples include downloading and utilizing ... free websites that help people monetize the assets they didn't ... unused items they can find in their garage. , ...
(Date:7/29/2014)... July 30, 2014 Dignity Sciences Limited, ... completion of a Phase I trial with DS107G, an ... This study was a randomized, placebo-controlled, double-blind, single-ascending and ... safety, pharmacokinetics and effect of food on DS107G in ... safety profile of DGLA following both single and multiple ...
(Date:7/29/2014)... Use of electroacupuncture (EA) a form of ... between pairs of acupuncture needles produces significant ... little as eight weeks for early stage breast ... use of aromatase inhibitors (AIs) to treat breast ... examining the intervention led by researchers at the ...
Breaking Medicine News(10 mins):Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 2Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 3Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 2Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 3Health News:Create Indestructible Wealth Launches Innovative E-Book: “Realistic Ways to Make More Money in 30 Days” 2Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 3
... S.C., Dec. 11 African-American women in South Carolina are 37 ... have a death rate that is about 61 percent higher, according ... Arnold School of Public Health. , (View a video of Dr. ... in the nation in deaths from cervical cancer. , The study ...
... 10, 2009 The advice of a pediatrician to place infants ... important motivator in getting parents to follow these recommendations and a ... plummeted since the "Back to Sleep" campaign was launched in 1994, ... shown that placing infants on their backs to sleep limits the ...
... those in uncommitted relationships , FRIDAY, Dec. 11 ... are no more likely than those in committed relationships ... In the study, University of Minnesota researchers analyzed the ... 20.5, who were asked about their sexual behaviors and ...
... , Immediate action needed to protect public ... 11 It,s been almost two weeks since the Food ... of a new safety assessment of the toxic plastics chemical ... and pregnant women are left unprotected from this hormone-disrupting compound ...
... , AUSTIN, Texas, Dec. 11 ... pleased to offer free upgrades to their customers currently using Dragon ... is faster and more stable, providing up to 99% accuracy ... with Windows7, 64bit and 32bit operating systems. New features include voice ...
... , BEIJING, Dec. ... CCM ) ("CMS" or "the Company"), operator of the largest,network ... of,revenues and the total number of centers in operation in ... Depositary Shares,("ADSs"), each representing three ordinary shares of the Company, ...
Cached Medicine News:Health News:'Disease of Poverty': University of South Carolina Releases Journal on Cervical Cancer, Health Disparities 2Health News:'Disease of Poverty': University of South Carolina Releases Journal on Cervical Cancer, Health Disparities 3Health News:Physician advice a key motivator in baby's sleep position 2Health News:Physician advice a key motivator in baby's sleep position 3Health News:Casual Sex Doesn't Cause Emotional Damage: Study 2Health News:When Will FDA Speak Out on Toxic Plastics Chemical BPA? 2Health News:Recorders.com Offers Free Dragon Medical 10.1 Upgrades 2Health News:Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange 2Health News:Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange 3
(Date:7/29/2014)... CAMBRIDGE, Mass. and HERZLIYA PITUACH, ... Inc. (OTCQX and NASDAQ OMX First North Premier, ... announces today that it has initiated the screening of ... trial exploring the safety and efficacy of bertilimumab in ... open-label trial will enroll 10-15 patients who will receive ...
(Date:7/29/2014)... 29, 2014  Sequenom, Inc. (NASDAQ: SQNM ... solutions, today reported total revenues of $39.8 million for ... compared to revenues of $24.5 million for the second ... segment, which was sold on May 30, 2014, has ... its results have been excluded from continuing operations for ...
(Date:7/29/2014)... 2014  EnteroMedics Inc. (NASDAQ: ETRM ), ... treat obesity, metabolic diseases and other gastrointestinal disorders, today ... Thursday, August 7, 2014 at 11:00 AM Eastern Time ... June 30, 2014 and to provide a business update. ... quarter conference call may be accessed by dialing (877) ...
Breaking Medicine Technology:Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 3Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 4Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 5Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 2Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 3Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 4Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 5Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 6Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 7Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 8Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 9Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 10Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 11Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 12Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 13Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 14Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 15Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 16EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3
... Corporation (NASDAQ: VOLC ), a leading developer and ... the diagnosis and treatment of coronary and peripheral vascular disease, ... the third quarter of fiscal 2011 on Monday, October 31. ... discuss its financial results and operating activities open to all ...
... 17, 2011 Archimedes Pharma Ltd., and its subsidiary, ... nasal spray is now available by prescription in U.S. ... pain in cancer patients 18 years of age and ... to opioid therapy for their underlying persistent cancer pain. ...
Cached Medicine Technology:Volcano Corporation Schedules Third Quarter Conference Call, Webcast 2Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 2Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 3Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 4Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 5Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 6Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 7
For use with E5381 600 Circling Band (40 style). 2.2 mm diameter, 28.5 mm long....
Used with Double Tantalum Clip (250 style) E5381 852. Overall length: 7.0 mm....
Concave inner surface to conform to globe. Used in conjunction with the E5381 700 Circling Band (240 style). Indications: wide scleral bed. Outside diameter 31.7 mm....
Used in conjunction with the E5381 700 Circling Band (240 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
Medicine Products: